Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients
Launched by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST · May 17, 2013
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with an MDT diagnosis of NSCLC based on findings of positive histology, positive PET scan or growth on serial CT scan requiring CT planning for radiotherapy treatment
- • patients aged over 18
- • patients able to undergo MRI scanning.
- Exclusion Criteria:
- • patients with co-morbid conditions that exclude radiotherapy treatment
- • patients who are pregnant or women with child bearing potential
- • patients unable to give informed consent
- • patients who do not understand English sufficiently to read the patient information sheet, provide informed consent or converse with research staff without interpreters.
About Sheffield Teaching Hospitals Nhs Foundation Trust
Sheffield Teaching Hospitals NHS Foundation Trust is a leading healthcare institution in the UK, dedicated to delivering high-quality patient care, advancing medical research, and fostering education and training in the health sector. As a prominent sponsor of clinical trials, the Trust collaborates with various stakeholders to facilitate innovative research initiatives that aim to improve treatment outcomes and enhance patient safety. With a commitment to excellence, the organization leverages its extensive clinical expertise and resources to support the development of new therapies and interventions, ultimately contributing to the advancement of healthcare practices both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sheffield, , United Kingdom
Patients applied
Trial Officials
Matthew Q Hatton, FRCR, FRCP
Principal Investigator
University of Sheffield
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials